A型和B型肉毒杆菌毒素：痉挛性发声障碍的对比剂量研究
Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.
作者信息
Blitzer Andrew
机构信息
College of Physicians and Surgeons, Columbia University, New York Center for Voice and Swallowing Disorders, New York, NY 10019, USA.
出版信息
Otolaryngol Head Neck Surg. 2005 Dec;133(6):836-8. doi: 10.1016/j.otohns.2005.09.008.
OBJECTIVE
The purpose of this study was to find the conversion factor, safety, and efficacy of type A to type B toxin for laryngeal muscles.
METHODS
Thirty-two patients with adductor spasmodic dysphonia with stable doses of A toxin to manage their symptom were given type B toxin starting at a conversion of 1 U of BTX-A to 50 U of BTX-B. The patients were followed for 1 year, and doses adjusted according to response.
RESULTS
The conversion factor was found to be 52.3 U:1 U. The onset of action of type B was more rapid (2.09 days vs 3.2 days [P = 0.028]), with a shorter duration of benefit (10.8 weeks vs 17 weeks [P = 0.002). The safety profile for A and B toxin appeared the same, with 3 patients receiving Myobloc reporting dry mouth.
CONCLUSION
This study shows that a conversion factor of 52.3:1 Myobloc (BTX-B) to Botox (BTX-A) and that Myobloc is an effective alternative to Botox (BTX-A) for patients with spasmodic dysphonia.
目的
本研究旨在探寻A型毒素转换为B型毒素用于喉肌时的转换因子、安全性及有效性。
方法
对32例服用稳定剂量A型毒素控制症状的内收型痉挛性发声障碍患者给予B型毒素，起始转换比例为1单位肉毒素A转换为50单位肉毒素B。对患者进行为期1年的随访，并根据反应调整剂量。
结果
发现转换因子为52.3单位B型毒素：1单位A型毒素。B型毒素起效更快（2.09天对3.2天[P = 0.028]），获益持续时间更短（10.8周对17周[P = 0.002]）。A型和B型毒素的安全性表现相同，3例接受Myobloc治疗的患者报告有口干症状。
结论
本研究表明，肉毒素B（Myobloc）与肉毒素A（Botox）的转换因子为52.3:1，且对于痉挛性发声障碍患者，肉毒素B是肉毒素A的有效替代药物。
Zotero 插件